Voyager Therapeutics, Inc.
VYGR
$4.15
$0.030.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -83.09% | 14.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.09% | 14.75% | |||
| Cost of Revenue | -26.68% | -6.45% | |||
| Gross Profit | -20.82% | 19.04% | |||
| SG&A Expenses | 0.55% | 1.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.32% | -4.98% | |||
| Operating Income | -14.52% | 13.60% | |||
| Income Before Tax | -1.85% | 1.41% | |||
| Income Tax Expenses | 55.56% | -89.16% | |||
| Earnings from Continuing Operations | -1.86% | 1.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.86% | 1.67% | |||
| EBIT | -14.52% | 13.60% | |||
| EBITDA | -15.58% | 14.43% | |||
| EPS Basic | -0.92% | 1.90% | |||
| Normalized Basic EPS | -15.65% | 14.21% | |||
| EPS Diluted | 0.13% | 0.86% | |||
| Normalized Diluted EPS | -15.65% | 14.21% | |||
| Average Basic Shares Outstanding | 0.95% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.95% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||